Anti-viral photodynamic therapy in COVID-19 management: a novel approach in treating patients in early infection stages

Successful reduction of SARS-CoV-2 viral load by photodynamic therapy verified by quantitative PCR – a novel approach in treating patients in early infection stages

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10839729

Enrollment

140

Registered

2021-04-29

Start date

2020-11-01

Completion date

Unknown

Last updated

2021-05-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 (SARS-CoV-2 infection) Infections and Infestations

Interventions

Patients are assigned in the sequence of hospital admission to two groups with 70 patients in the experiment (verum) group receiving daily Photodynamic Therapy and daily testing for 5 days and a contr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Men and women 2. Aged 10-90 years 3. Early stages of COVID-19 (SARS-CoV-2 infection)

Exclusion criteria

Exclusion criteria: 1. Late infection stages 2. Pregnant women 3. Children aged under 10 years

Design outcomes

Primary

Measure	Time frame
Viral load measured using the QPCR test (Ct value) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours	—

Secondary

Measure	Time frame
Clinical symptoms measured using the visual analogue score (VAS) at baseline, 24 hours, 48 hours, 72 hours, 96 hours, 120 hours and 168 hours	—

Countries

Iran

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026